Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820119 | 0.87 | PTPN1 (0.71) | SMN1; SMN2PTPN1PTPN11RAB9ANPC1 | |
| SCHEMBL6964944 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Benzene SCHEMBL28977956 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL57554 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL9856061 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL9363961 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Hydrazine SCHEMBL28432690 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL616739 | 0.80 | PTPN11 (0.75) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL992038 | 0.80 | EPHX2 (0.64) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL2680094 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53EPHX1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238095-A1 | OXADIAZOLE OXIME DERIVATIVE AND USE THEREOF IN AGRICULTURE | 东莞市东阳光农药研发有限公司 | 2019-12-19 | — | — | WO | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080242700-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2008-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1650189-A1 | BENZYLAMINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-1242069-B1 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-1988007534-A1 | BETA-LACTAM EPOXIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-10-06 | — | — | WO | disclosed |
| US-4656183-A | Pesticidal oxalyl dianilides | CIBA-GEIGY CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| US-4556739-A | QUINAZOLINONE INTERMEDIATES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
| US-4555570-A | Substituted 4-alkyl-2-(1H) quinazolinone-1-alkanoic acid derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138492-A2 | Process for preparing substituted 4-alkyl-2(1H) quinazolinone-1-alkanoic acid derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | SMN1; SMN2 2474/4885TP53 252/4885EPHX1 2556/4885 |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | SMN1; SMN2 4234/4885TP53 3804/4885EPHX1 345/4885 |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | KCNAB1, BDKRB2, ARRB1 | SMN1; SMN2 3119/4885TP53 4348/4885EPHX1 2119/4885 |
| US-20080242700-A1 | Methods and Compositions for Selectin Inhibition | SELE, SELP, SELL | SMN1; SMN2 1477/4885TP53 3572/4885EPHX1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.